Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

BioAge Labs (BIOA) Shares Issued (2024 - 2026)

BioAge Labs' Shares Issued history spans 1 years, with the latest figure at -$174.3 million for Q4 2024.

On a quarterly basis, Shares Issued changed N/A to -$174.3 million in Q4 2024 year-over-year; TTM through Sep 2025 was -$174.3 million, a N/A change, with the full-year FY2024 number at $9.9 million, up 246350.0% from a year prior.
Shares Issued hit -$174.3 million in Q4 2024 for BioAge Labs, down from $183.7 million in the prior quarter.
Over the last five years, Shares Issued for BIOA hit a ceiling of $183.7 million in Q3 2024 and a floor of -$174.3 million in Q4 2024.